FI906367A0 - Terapeutiska nukleosider. - Google Patents
Terapeutiska nukleosider.Info
- Publication number
- FI906367A0 FI906367A0 FI906367A FI906367A FI906367A0 FI 906367 A0 FI906367 A0 FI 906367A0 FI 906367 A FI906367 A FI 906367A FI 906367 A FI906367 A FI 906367A FI 906367 A0 FI906367 A0 FI 906367A0
- Authority
- FI
- Finland
- Prior art keywords
- nucleosider
- therapeutic
- therapeutic nucleosider
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI970666A FI105813B (fi) | 1989-12-22 | 1997-02-17 | Enantiomeerisia välituotteita |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45520189 | 1989-12-22 | ||
| US07/455,201 US5034394A (en) | 1988-06-27 | 1989-12-22 | Therapeutic nucleosides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI906367A0 true FI906367A0 (fi) | 1990-12-21 |
| FI906367A FI906367A (fi) | 1991-06-23 |
| FI106461B FI106461B (fi) | 2001-02-15 |
Family
ID=23807819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI906367A FI106461B (fi) | 1989-12-22 | 1990-12-21 | Menetelmä terapeuttisesti käyttökelpoisten enantiomeeristen yhdisteiden valmistamiseksi sekä menetelmässä käyttökelpoinen välituote |
| FI20001175A FI20001175A (fi) | 1989-12-22 | 2000-05-16 | Enantiomeerisia yhdisteitä, jotka ovat oleellisesti vapaita vastaenantiomeereista |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20001175A FI20001175A (fi) | 1989-12-22 | 2000-05-16 | Enantiomeerisia yhdisteitä, jotka ovat oleellisesti vapaita vastaenantiomeereista |
Country Status (30)
| Country | Link |
|---|---|
| EP (3) | EP0921121A1 (fi) |
| JP (2) | JPH11158160A (fi) |
| CN (1) | CN1028106C (fi) |
| AP (1) | AP196A (fi) |
| AT (1) | ATE181917T1 (fi) |
| AU (1) | AU633672B2 (fi) |
| CA (1) | CA2033044C (fi) |
| CY (1) | CY2145B1 (fi) |
| CZ (1) | CZ283481B6 (fi) |
| DE (2) | DE69033197T2 (fi) |
| DK (1) | DK0434450T3 (fi) |
| ES (1) | ES2133138T3 (fi) |
| FI (2) | FI106461B (fi) |
| GR (1) | GR3031100T3 (fi) |
| HK (1) | HK1009600A1 (fi) |
| HU (3) | HU220067B (fi) |
| IE (3) | IE990826A1 (fi) |
| IL (1) | IL96748A (fi) |
| LU (1) | LU90426I2 (fi) |
| MX (1) | MX9203215A (fi) |
| MY (1) | MY104575A (fi) |
| NL (1) | NL990028I2 (fi) |
| NZ (1) | NZ236593A (fi) |
| PL (1) | PL167097B1 (fi) |
| PT (1) | PT96321B (fi) |
| RU (2) | RU2068849C1 (fi) |
| SG (1) | SG49685A1 (fi) |
| SK (2) | SK658390A3 (fi) |
| TW (2) | TW473466B (fi) |
| ZA (1) | ZA9010365B (fi) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2010091A6 (es) * | 1988-01-20 | 1989-10-16 | Univ Minnesota | Un metodo para preparar compuestos analogos a nucleosidos didesoxicarbociclicos. |
| CA2001401A1 (en) * | 1988-10-25 | 1990-04-25 | Claude Piantadosi | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
| GB9108376D0 (en) * | 1991-04-19 | 1991-06-05 | Enzymatix Ltd | Cyclopentenes |
| GB9204015D0 (en) * | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
| GB9205071D0 (en) * | 1992-03-09 | 1992-04-22 | Wellcome Found | Therapeutic nucleosides |
| DE69431596D1 (de) * | 1993-06-10 | 2002-11-28 | Wake Forest University Winston | (phospho)lipide zum bekämpfen einer hepatitis b-infektion |
| GB9402161D0 (en) * | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
| GB9417249D0 (en) * | 1994-08-26 | 1994-10-19 | Wellcome Found | A novel salt |
| ATE395922T1 (de) | 1994-08-29 | 2008-06-15 | Univ Wake Forest | Lipid-analoge zur behandlung von viralen infektionen |
| US7135584B2 (en) | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| GB9600142D0 (en) * | 1996-01-05 | 1996-03-06 | Wellcome Found | Chemical compounds |
| BR9709939A (pt) | 1996-06-25 | 1999-08-10 | Glaxo Group Ltd | Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente |
| KR20000022225A (ko) | 1996-06-25 | 2000-04-25 | 그레이엄 브레레톤;레슬리 에드워즈 | Hiv 치료에 사용하기 위한 vx478, 지도부딘 및(또는)1592u89를 포함하는 배합물 |
| SK285228B6 (sk) * | 1997-05-13 | 2006-09-07 | Lonza Ag | Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén |
| AU769660B2 (en) * | 1997-05-17 | 2004-01-29 | Glaxo Group Limited | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
| GB9709945D0 (en) * | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
| GB9721780D0 (en) * | 1997-10-14 | 1997-12-10 | Glaxo Group Ltd | Process for the synthesis of chloropurine intermediates |
| AU2702899A (en) * | 1997-10-24 | 1999-05-17 | Glaxo Group Limited | Process for preparing a chiral nucleoside analogue |
| WO1999024431A1 (en) * | 1997-11-12 | 1999-05-20 | Glaxo Group Limited | Process for preparing a chiral nucleoside analogue |
| CZ298144B6 (cs) * | 1997-11-27 | 2007-07-04 | Lonza Ag | Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| GB9802472D0 (en) * | 1998-02-06 | 1998-04-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| GB9821058D0 (en) | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| SK285271B6 (sk) * | 1998-10-30 | 2006-10-05 | Lonza Ag | Spôsob výroby 4-[(2',5'-diamino-6'-halogénpyrimidin-4'- yl)amino]cyklopent-2-enylmetanolov |
| US6433170B1 (en) | 1998-10-30 | 2002-08-13 | Lonza Group | Method for producing 4-[2',5'-diamino-6'-halopyrimidine-4'-yl)amino]- cyclopent-2-enylmethanols |
| GB9903091D0 (en) * | 1999-02-12 | 1999-03-31 | Glaxo Group Ltd | Therapeutic nucleoside compound |
| US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| EP1235834A1 (en) * | 1999-12-10 | 2002-09-04 | Glaxo Group Limited | (1r,cis)-4-(4-amino-7h-pyrr0l0[2,3- i(d)]pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral |
| PE20010915A1 (es) * | 1999-12-10 | 2001-09-29 | Glaxo Group Ltd | Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales |
| DE10042655A1 (de) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| BRPI0210746B8 (pt) | 2001-06-29 | 2021-05-25 | Inst Of Organic Chemistry And Biochemistry Ascr | derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina e seu método de preparação |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US7550261B2 (en) | 2001-08-21 | 2009-06-23 | Smithkline Beecham Corporation | Method of screening for drug hypersensitivity reaction |
| AU2002323034A1 (en) * | 2001-08-21 | 2003-03-10 | Glaxo Group Limited | Method of screening for drug hypersensitivity reaction |
| CN100469131C (zh) | 2001-08-31 | 2009-03-11 | 汤姆森许可公司 | 实现条件存取系统和传输、接收及处理内容的方法和设备 |
| US6780635B2 (en) | 2001-12-27 | 2004-08-24 | Council Of Scientific And Industrial Research | Process for the preparation of optically active azabicyclo heptanone derivatives |
| DE60303131T2 (de) * | 2002-06-27 | 2006-07-20 | Medivir Ab | Synergistische wechselwirkung von abacavir und alovudin |
| ATE496056T1 (de) | 2003-06-16 | 2011-02-15 | Acad Of Science Czech Republic | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga |
| GB0320738D0 (en) | 2003-09-04 | 2003-10-08 | Glaxo Group Ltd | Novel process |
| EP1857458A1 (en) * | 2006-05-05 | 2007-11-21 | SOLMAG S.p.A. | Process for the preparation of abacavir |
| EP1905772A1 (en) * | 2006-09-28 | 2008-04-02 | Esteve Quimica, S.A. | Process for the preparation of abacavir |
| JP5334852B2 (ja) * | 2006-09-28 | 2013-11-06 | エステヴェ キミカ， エス．エー． | アバカビルの製造方法 |
| EP1939196A1 (en) | 2006-12-21 | 2008-07-02 | Esteve Quimica, S.A. | Process for the preparation of abacavir |
| CN101328171A (zh) | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| EP2085397A1 (en) | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| KR101669297B1 (ko) | 2008-09-09 | 2016-10-25 | 아스트라제네카 아베 | [1Ｓ-[1-알파,2-알파,3-베타(1Ｓ*,2Ｒ*),5-베타]]-3-[7-[2-(3,4-디플루오로페닐)-사이클로프로필아미노]-5-(프로필티오)-3Ｈ-1,2,3-트리아졸로[4,5-ｄ]피리미딘-3-일]-5-(2-하이드록시에톡시)사이클로펜탄-1,2-디올의 제조 방법 및 그 중간체 |
| BR112014016615A8 (pt) * | 2012-01-03 | 2017-07-04 | Cellceutix Corp | nucleosídios carbocíclicos, seus usos farmacêuticos e composições |
| US9457028B2 (en) | 2013-02-27 | 2016-10-04 | Kyoto University | Pharmaceutical composition for use in prevention or treatment of cancer |
| IN2013MU03145A (fi) | 2013-10-03 | 2015-07-03 | Lupin Ltd | |
| CN104558035B (zh) * | 2013-10-22 | 2017-12-19 | 连云港恒运药业有限公司 | 一种替诺福韦前药的纯化方法 |
| CN104788451A (zh) * | 2014-01-21 | 2015-07-22 | 浙江九洲药业股份有限公司 | 一种阿巴卡韦的制备方法 |
| CN109239253B (zh) * | 2018-09-21 | 2021-07-09 | 江苏威奇达药业有限公司 | 一种阿巴卡韦的杂质的高效液相检测方法 |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT86377B (pt) * | 1986-12-24 | 1990-11-20 | Lilly Co Eli | Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado |
| ES2010091A6 (es) * | 1988-01-20 | 1989-10-16 | Univ Minnesota | Un metodo para preparar compuestos analogos a nucleosidos didesoxicarbociclicos. |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| EP0366385B1 (en) * | 1988-10-24 | 1993-06-09 | The Wellcome Foundation Limited | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts |
| NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
| US4939252A (en) * | 1989-04-20 | 1990-07-03 | Hoffmann-La Roche Inc. | Novel intermediates for the preparation of Carbovir |
-
1990
- 1990-12-20 MY MYPI90002230A patent/MY104575A/en unknown
- 1990-12-21 FI FI906367A patent/FI106461B/fi active Protection Beyond IP Right Term
- 1990-12-21 AU AU68419/90A patent/AU633672B2/en not_active Expired
- 1990-12-21 HU HU9902539A patent/HU220067B/hu unknown
- 1990-12-21 EP EP99103525A patent/EP0921121A1/en not_active Withdrawn
- 1990-12-21 PT PT96321A patent/PT96321B/pt not_active IP Right Cessation
- 1990-12-21 SK SK6583-90A patent/SK658390A3/sk not_active IP Right Cessation
- 1990-12-21 ES ES90314089T patent/ES2133138T3/es not_active Expired - Lifetime
- 1990-12-21 EP EP90314089A patent/EP0434450B1/en not_active Expired - Lifetime
- 1990-12-21 HU HU407/90A patent/HU219454B/hu unknown
- 1990-12-21 RU SU904894161A patent/RU2068849C1/ru active
- 1990-12-21 CA CA002033044A patent/CA2033044C/en not_active Expired - Lifetime
- 1990-12-21 IE IE19990826A patent/IE990826A1/en unknown
- 1990-12-21 DK DK90314089T patent/DK0434450T3/da active
- 1990-12-21 DE DE69033197T patent/DE69033197T2/de not_active Expired - Lifetime
- 1990-12-21 AP APAP/P/1990/000234A patent/AP196A/en active
- 1990-12-21 IL IL9674890A patent/IL96748A/en not_active IP Right Cessation
- 1990-12-21 AT AT90314089T patent/ATE181917T1/de active
- 1990-12-21 EP EP99103526A patent/EP0921114A1/en not_active Withdrawn
- 1990-12-21 PL PL90288403A patent/PL167097B1/pl unknown
- 1990-12-21 CN CN91100671A patent/CN1028106C/zh not_active Expired - Lifetime
- 1990-12-21 CZ CS906583A patent/CZ283481B6/cs not_active IP Right Cessation
- 1990-12-21 DE DE1990633197 patent/DE19975058I1/de active Pending
- 1990-12-21 NZ NZ236593A patent/NZ236593A/en unknown
- 1990-12-21 IE IE465290A patent/IE904652A1/en not_active IP Right Cessation
- 1990-12-21 IE IE19990825A patent/IE990825A1/en unknown
- 1990-12-21 HU HU9902543A patent/HU220630B1/hu unknown
- 1990-12-21 SG SG1996004082A patent/SG49685A1/en unknown
- 1990-12-21 ZA ZA9010365A patent/ZA9010365B/xx unknown
-
1991
- 1991-04-09 TW TW088111311A patent/TW473466B/zh not_active IP Right Cessation
- 1991-04-09 TW TW080102699A patent/TW371660B/zh not_active IP Right Cessation
-
1992
- 1992-06-04 RU SU925011830A patent/RU2091386C1/ru active
- 1992-06-24 MX MX9203215A patent/MX9203215A/es active IP Right Grant
- 1992-08-10 SK SK2470-92A patent/SK280000B6/sk not_active IP Right Cessation
-
1998
- 1998-08-31 HK HK98110320A patent/HK1009600A1/xx not_active IP Right Cessation
- 1998-09-28 JP JP10273408A patent/JPH11158160A/ja active Pending
-
1999
- 1999-05-06 JP JP11126185A patent/JPH11343292A/ja active Pending
- 1999-08-06 LU LU90426C patent/LU90426I2/fr unknown
- 1999-08-26 GR GR990402183T patent/GR3031100T3/el unknown
- 1999-09-14 NL NL990028C patent/NL990028I2/nl unknown
- 1999-12-09 CY CY9900044A patent/CY2145B1/xx unknown
-
2000
- 2000-05-16 FI FI20001175A patent/FI20001175A/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI906367A (fi) | Terapeutiska nukleosider. | |
| FI913899A0 (fi) | Terapeutiska aerosolblandningar. | |
| DE68921798D1 (de) | Therapeutische Nuleoside. | |
| FI903656A0 (fi) | Terapeutiska kinuklidinfoereningar. | |
| FI883757A0 (fi) | Terapeutiska nukleosider. | |
| FI881651A (fi) | Terapeutiska nukleosider. | |
| FI903873A0 (fi) | Foerbaettrad skaeruppbaeringstrumenhet foer flismaskin. | |
| FI914805A0 (fi) | Ickegrafitiska taendningsresistanta strukturer. | |
| FI904854A0 (fi) | Terapeutiska nukleosider. | |
| FI902973A0 (fi) | Magnetfaeltsgenerator foer terapeutiska aendamaol. | |
| FI905632A0 (fi) | Imidazolfungicider. | |
| FI893897A (fi) | Terapeutiska nukleosider. | |
| FI923486A0 (fi) | Terapeutiska aemnen. | |
| FI881216A0 (fi) | Terapeutiska nukleosider. | |
| FI894321A0 (fi) | Terapeutiska aemnen. | |
| FI910753A (fi) | Terapeutiska nukleocider. | |
| FI923528A (fi) | Terapeutiska aemnen. | |
| FI912852A0 (fi) | Terapeutiska dekapeptider. | |
| NO901573D0 (no) | Terapeutiske midler. | |
| NO901574D0 (no) | Terapeutiske midler. | |
| FI892374A0 (fi) | Anordning foer foerflyttning av patient. | |
| FI891231A0 (fi) | Anordning foer foerflyttning av patient. | |
| FI893989A0 (fi) | Inlaeggssula. | |
| FI893043A0 (fi) | Laosningsanordning. | |
| FI892970A0 (fi) | Akustisk bullergenerator. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: THE WELLCOME FOUNDATION LIMITED |
|
| SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L190 Extension date: 20140627 |